A former Celgene Corp. saleswoman who blew the whistle on allegedly improper marketing tactics at the drug company was cleared Tuesday to collect a $78 million bounty that’s been held up amid a dispute between whistleblower attorney Reuben Guttman and his former law firm, Grant & Eisenhofer.

U.S. District Judge Philip Gutierrez in Los Angeles agreed to strike down an attorney’s charging lien that Grant & Eisenhofer asserted against a whistleblower award heading to Beverly Brown, a former Celgene employee who brought a False Claims Act lawsuit against the company. Brown’s false claims suit alleged that Celgene promoted a pair of cancer drugs, Thalomid and Revlimid, for off-label uses that weren’t approved by the U.S. Food and Drug Administration.